Is DNLI or EIKN more undervalued in 2026?

CirclFi compares Denali Therapeutics Inc. (DNLI) and Eikon Therapeutics, Inc. (EIKN) using 13 institutional-grade valuation models. DNLI has a Quality of Company score of 6.9/10 while EIKN scores 1.7/10.

Which is a better buy — DNLI or EIKN?

Compare intrinsic values from 13 independent models against current market prices. CirclFi also calculates Value Trap scores. This is not financial advice — conduct your own analysis.

How do DNLI and EIKN valuations compare?

DNLI at $21.04 and EIKN at $10.84 are compared across Bayesian DCF, EPV, EROIC Spread, First Chicago, Markov DDM, and 8 additional models.

DNLI vs EIKN Valuation Comparison 2026 — Intrinsic Value Analysis

DNLI

Biological Products, (No Diagnostic Substances)

Denali Therapeutics Inc.

Quality

6.9

out of 10

Value Trap

SAFE

Price

$21.04

Last close

Models

12/13

Active

EIKN

Biological Products, (No Diagnostic Substances)

Eikon Therapeutics, Inc.

Quality

1.7

out of 10

Value Trap

—

Price

$10.84

Last close

Models

7/13

Active

Model-by-Model Comparison

Model	Type	DNLI Fair Value	DNLI Upside	EIKN Fair Value	EIKN Upside
Bayesian DCF	Intrinsic	$5.29	-74.9%	$2.80	-74.1%
Earnings Power Value	Intrinsic	$9.00	-54.7%	—	—
EROIC Spread	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
First Chicago	Scenario	$•••.••	••.•%	$•••.••	••.•%
Markov DDM	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
ML-RIV	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
Dynamic NAV	Asset-Based	$•••.••	••.•%	$•••.••	••.•%
PWERM	Option-Based	$19.44	-7.6%	$5.58	-48.5%
Regime Cross-Sectional	Relative	$•••.••	••.•%	$•••.••	••.•%
Sentiment SOTP	Hybrid	$•••.••	••.•%	$•••.••	••.•%
CUCE Ensemble	Ensemble	$•••.••	••.•%	$•••.••	••.•%
FTNN Topology	Relative	$•••.••	••.•%	$•••.••	••.•%

🔒

Unlock Full 13-Model Comparison

Access all valuation models for DNLI vs EIKN — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

DNLI vs EIKN — Which Stock Is More Undervalued?

DNLI scores higher with a 6.9/10 quality rating vs EIKN's 1.7/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Denali Therapeutics Inc. (DNLI) and Eikon Therapeutics, Inc. (EIKN) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

DNLI currently trades at $21.04 with a QOC of 6.9/10, while EIKN trades at $10.84 with a QOC of 1.7/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).